Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI Taiwan ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI Taiwan ETF trades at $114.92 (market cap $12.87B). The key difference: iShares MSCI Taiwan ETF is far larger — about 1923.8× Enveric Biosciences Inc's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI Taiwan ETF for 52 Days on average.
| ENVB | EWT | |
|---|---|---|
Market Cap | $6.69M | $12.87B |
Volume | 41,141 | 4,043,927 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $118.00 |
52-Week Low | $1.27 | $60.03 |
Typical Hold Time | 14 Days | 52 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
EWT trades at $116.24, down 1.16% today, with a bullish technical outlook supported by moving averages. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights continued US-Taiwan economic cooperation and institutional buying interest.
The outlook remains positive given Taiwan's strategic position in AI supply chains, though geopolitical tensions pose significant risks. Valuation appears reasonable for tech exposure, but investors must weigh semiconductor cyclicality against long-term growth potential in artificial intelligence infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
